AZ/MSD’s Lynparza assigned Orphan status in US
admin 17th October 2018 Uncategorised 0AstraZeneca and MSD’s PARP inhibitor Lynparza has been granted orphan drug designation in the US for the treatment of pancreatic cancer.
More: AZ/MSD’s Lynparza assigned Orphan status in US
Source: News